No Joy In Bayer/Onyx’s Phase III With Nexavar For Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Second sorafenib failure comes three months after Synta/GlaxoSmithKline’s elesclomol blow-up in the tough-to-crack cancer.
You may also be interested in...
Bristol Bid For ZymoGenetics Looks Even Better In Light Of Promising Melanoma Data
ZymoGenetics shareholders who want a better offer than the $885 million acquisition Bristol-Myers Squibb offered on Wednesday, September 8, aren’t likely to get one. It’s a disappointing result for a company with nearly 30 years of biotech discovery and grand ambitions behind it.
Bristol Bid For ZymoGenetics Looks Even Better In Light Of Promising Melanoma Data
ZymoGenetics shareholders who want a better offer than the $885 million acquisition Bristol-Myers Squibb offered on Wednesday, September 8, aren’t likely to get one. It’s a disappointing result for a company with nearly 30 years of biotech discovery and grand ambitions behind it.
Bayer/Onyx Pharma’s Nexavar Among MHLW’s Pre-Golden Week Approval Rush
Japan's Ministry of Health, Labor and Welfare's drug approval advisory body, the Pharmaceutical Affairs and Food Sanitization Council's second committee on new drugs April 27 recommended Bayer/Onyx Pharmaceuticals' Nexavar (sorafenib) for approval for the additional indication of advanced hepatocellular carcinoma